First Citizens Bank & Trust Co. Buys 26,752 Shares of ADMA Biologics Inc $ADMA

First Citizens Bank & Trust Co. raised its stake in ADMA Biologics Inc (NASDAQ:ADMA) by 201.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 40,050 shares of the biotechnology company’s stock after purchasing an additional 26,752 shares during the period. First Citizens Bank & Trust Co.’s holdings in ADMA Biologics were worth $729,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Skandinaviska Enskilda Banken AB publ bought a new stake in shares of ADMA Biologics during the 1st quarter worth about $35,000. SVB Wealth LLC bought a new position in ADMA Biologics in the 1st quarter valued at about $35,000. Cullen Frost Bankers Inc. lifted its position in ADMA Biologics by 112.5% during the second quarter. Cullen Frost Bankers Inc. now owns 2,042 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,081 shares during the last quarter. Toth Financial Advisory Corp lifted its position in ADMA Biologics by 1,081.6% during the second quarter. Toth Financial Advisory Corp now owns 2,505 shares of the biotechnology company’s stock worth $46,000 after acquiring an additional 2,293 shares during the last quarter. Finally, Ameritas Advisory Services LLC bought a new stake in shares of ADMA Biologics during the second quarter worth approximately $46,000. 75.68% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered ADMA Biologics from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $27.67.

ADMA Biologics Stock Performance

Shares of NASDAQ:ADMA opened at $15.18 on Friday. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67. The company’s 50 day moving average price is $15.81 and its two-hundred day moving average price is $18.25. The firm has a market cap of $3.62 billion, a PE ratio of 17.65 and a beta of 0.47. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. The company had revenue of $121.98 million during the quarter, compared to the consensus estimate of $121.77 million. ADMA Biologics had a net margin of 44.06% and a return on equity of 41.01%. The firm’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the business earned $0.13 earnings per share. Equities research analysts predict that ADMA Biologics Inc will post 0.51 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.